Livingston Group Asset Management CO operating as Southport Capital Management reduced its position in Baxter International Inc (NYSE:BAX) by 9.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,402 shares of the medical instruments supplier’s stock after selling 1,575 shares during the quarter. Livingston Group Asset Management CO operating as Southport Capital Management’s holdings in Baxter International were worth $1,288,000 at the end of the most recent quarter.
A number of other institutional investors have also recently made changes to their positions in BAX. Arjuna Capital boosted its stake in Baxter International by 1.8% during the 2nd quarter. Arjuna Capital now owns 29,375 shares of the medical instruments supplier’s stock valued at $2,406,000 after acquiring an additional 526 shares during the last quarter. National Pension Service boosted its stake in Baxter International by 8.2% during the 2nd quarter. National Pension Service now owns 586,393 shares of the medical instruments supplier’s stock valued at $48,026,000 after acquiring an additional 44,652 shares during the last quarter. Holocene Advisors LP bought a new position in Baxter International during the 2nd quarter valued at $1,516,000. A.R.T. Advisors LLC acquired a new stake in shares of Baxter International during the second quarter worth $287,000. Finally, AMP Capital Investors Ltd raised its holdings in shares of Baxter International by 9.4% during the second quarter. AMP Capital Investors Ltd now owns 229,632 shares of the medical instruments supplier’s stock worth $18,752,000 after purchasing an additional 19,650 shares during the period. 82.48% of the stock is owned by hedge funds and other institutional investors.
Shares of Baxter International stock traded down $0.21 on Thursday, hitting $89.35. The company had a trading volume of 765,722 shares, compared to its average volume of 2,401,485. The business has a 50-day simple moving average of $84.08 and a 200-day simple moving average of $84.25. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.78 and a quick ratio of 2.10. The company has a market cap of $45.55 billion, a PE ratio of 29.30, a PEG ratio of 2.08 and a beta of 0.98. Baxter International Inc has a 52 week low of $67.40 and a 52 week high of $90.30.
The business also recently disclosed a quarterly dividend, which was paid on Thursday, January 2nd. Stockholders of record on Friday, December 6th were issued a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 0.98%. The ex-dividend date of this dividend was Thursday, December 5th. Baxter International’s dividend payout ratio (DPR) is presently 28.85%.
A number of analysts have weighed in on the stock. Deutsche Bank assumed coverage on shares of Baxter International in a report on Monday, October 21st. They set a “buy” rating and a $109.00 target price on the stock. JPMorgan Chase & Co. increased their target price on shares of Baxter International from $89.00 to $94.00 and gave the stock an “overweight” rating in a report on Friday, December 20th. UBS Group reaffirmed a “buy” rating and issued a $102.00 price objective on shares of Baxter International in a report on Monday. Wells Fargo & Co increased their price objective on shares of Baxter International from $95.00 to $100.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, Citigroup raised Baxter International from a “neutral” rating to a “buy” rating in a report on Thursday, January 2nd. Five investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $92.64.
In other news, Director John D. Forsyth sold 1,500 shares of the stock in a transaction that occurred on Friday, December 13th. The shares were sold at an average price of $83.64, for a total value of $125,460.00. Following the completion of the transaction, the director now directly owns 30,078 shares in the company, valued at $2,515,723.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.70% of the company’s stock.
Baxter International Profile
Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.
Further Reading: What is the Shanghai Stock Exchange Composite Index?
Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc (NYSE:BAX).
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.